INTERIM REPORT JANUARY-SEPTEMBER 2012 CHRONTECH PHARMA AB

  · Research and development costs amounted to SEK 10.7 (10.5) m
  · The loss after tax was SEK -14.9 (-13.9) m
  · Earnings per share were SEK -0.08 (-0.14)
  · The company had no net sales for the period
  · The patient recruitment for the controlled phase II clinical study of
ChronVac-C® in combination with standard-of-care is complete
  · The development of ChronTech’s IVIN technology progresses according to plan

For more information, please contact:

Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB

Mobile phone: +46 709 28 05 28,
E-mail: anders.vahlne@ki.se

About ChronTech

ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs
against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic
infections with jaundice causing viruses which can lead to liver cirrhosis and
liver cancer. ChronTech has also developed and further develops a patent pending
new type of injection needle for a more effective uptake of DNA vaccines.
ChronTech also have part ownership in the wound healing therapy ChronSeal®, and
in the new platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium Nordic AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.